The Cigna Group (CI) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
9 May, 2026Executive summary
Q1 2026 revenues rose 5% year-over-year to $68.5 billion, with adjusted EPS of $7.79, up 16%, and net income up 25% to $1.65 billion, driven by strong performance in Evernorth and Cigna Healthcare.
Adjusted income from operations increased 12% to $2.06 billion, with diluted EPS at $6.26, and shareholders' net income at $1.7 billion.
Raised full-year 2026 adjusted EPS outlook to at least $30.35, reflecting confidence in sustained growth.
Announced leadership transition: Brian Evanko to become CEO on July 1, with David Cordani moving to Executive Chair.
Proactive portfolio reshaping: exiting individual exchange business after 2026 and initiating strategic review of EviCore.
Financial highlights
Q1 2026 revenues: $68.5 billion; adjusted EPS: $7.79, up 16% year-over-year; adjusted income from operations: $2.06 billion (+12%).
Pharmacy revenues: $54.0 billion (+11%); fees/other revenues: $4.4 billion (+14%); premiums: $9.8 billion (–23% due to divestiture).
Evernorth revenues grew 9% to $58.4 billion; pre-tax adjusted earnings up 2% to $1.5 billion.
Specialty and Care Services pre-tax adjusted earnings up 20% to $1.1 billion; Pharmacy Benefit Services pre-tax adjusted earnings down 28% to $394 million.
After-tax special items charges of $322 million ($1.22 per share) recorded in Q1; strategic optimization program costs totaled $380 million pre-tax.
Outlook and guidance
Full-year 2026 adjusted EPS outlook raised to at least $30.35.
Evernorth full-year 2026 adjusted income from operations expected at least $6.9 billion; Cigna Healthcare at least $4.525 billion.
Cigna Healthcare Medical Care Ratio expected between 83.7% and 84.7% for 2026.
Second quarter adjusted EPS expected to be ~25% of full-year outlook; MCR to be slightly above high end of full-year range due to seasonality.
Management expects continued growth in Evernorth and improved margins in Cigna Healthcare, with ongoing investments in client-focused initiatives and cost management.
Latest events from The Cigna Group
- Board and management proposals passed; shareholder written consent proposal failed.CI
AGM 202622 Apr 2026 - Board recommends approval of all annual meeting items except the written consent proposal.CI
Proxy Filing13 Mar 2026 - Strong 2025 results, portfolio focus, and leadership transition headline this year’s proxy.CI
Proxy Filing13 Mar 2026 - Rebate-free PBM model and specialty pharmacy expansion drive growth and transparency.CI
TD Cowen 46th Annual Health Care Conference2 Mar 2026 - 2025 revenue up 11% to $275B; 2026 EPS guidance at least $30.25, FTC settlement resolved.CI
Q4 20255 Feb 2026 - Q2 revenue up 25%, adjusted EPS up 10%, and $3.7B Medicare sale expected in Q1 2025.CI
Q2 20242 Feb 2026 - EPS guidance reaffirmed, share repurchases prioritized, and specialty pharmacy drives growth.CI
Goldman Sachs 45th Annual Global Healthcare Conference1 Feb 2026 - Growth in specialty, pharmacy, and benefits segments drives innovation and strong financial outlook.CI
Morgan Stanley 22nd Annual Global Healthcare Conference22 Jan 2026 - Specialty drug growth and biosimilars drive market leadership and significant client savings.CI
Bernstein Healthcare 1:1 Forum 202420 Jan 2026